Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at Roth Capital
Actinium Pharmaceuticals Inc (AMEX:ATNM)‘s stock had its “buy” rating restated by equities research analysts at Roth Capital in a research report issued on Monday, StockTargetPrices.com reports. They currently have a $6.00 price target on the stock.
Separately, Maxim Group began coverage on shares of Actinium Pharmaceuticals in a research report on Thursday, September 14th. They set a “buy” rating and a $3.00 price objective for the company.
Shares of Actinium Pharmaceuticals (AMEX:ATNM) traded up 3.4621% during midday trading on Monday, hitting $0.7501. 994,873 shares of the company’s stock were exchanged. The firm’s market cap is $60.02 million. The company has a 50-day moving average of $0.65 and a 200-day moving average of $1.02. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.